Neosalvarsan

Last updated

Neosalvarsan
Neosalvarsan.svg
Neosalvarsan-3D-vdW.png
Names
Other names
Sodium 3,3'-diamino-4,4'-dihydroxyarsenobenzene-N-formaldehydesulfoxylate; Neoarsphenamine;914
Identifiers
3D model (JSmol)
ChemSpider
ECHA InfoCard 100.006.613 OOjs UI icon edit-ltr-progressive.svg
PubChem CID
UNII
  • InChI=1S/C13H14As2N2O4S.Na/c16-10-5-8(1-3-12(10)18)14-15-9-2-4-13(19)11(6-9)17-7-22(20)21;/h1-6,17-19H,7,16H2,(H,20,21);/q;+1/p-1 Yes check.svgY
    Key: BGYSJUFVJUJSOL-UHFFFAOYSA-M Yes check.svgY
  • InChI=1/C13H14As2N2O4S.Na/c16-10-5-8(1-3-12(10)18)14-15-9-2-4-13(19)11(6-9)17-7-22(20)21;/h1-6,17-19H,7,16H2,(H,20,21);/q;+1/p-1
    Key: BGYSJUFVJUJSOL-REWHXWOFAO
  • [Na+].[O-]S(=O)CNc2cc(/[As]=[As]/c1ccc(O)c(N)c1)ccc2O
Properties
C13H13As2N2NaO4S
Molar mass 466.15 g/mol
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Yes check.svgY  verify  (what is  Yes check.svgYX mark.svgN ?)

Neosalvarsan is a synthetic chemotherapeutic that is an organoarsenic compound. It became available in 1912 and superseded the more toxic and less water-soluble Salvarsan as an effective treatment for syphilis. Because both of these arsenicals carried considerable risk of side effects, they were replaced for this indication by penicillin in the 1940s.

Both Salvarsan and Neosalvarsan were developed in the laboratory of Paul Ehrlich in Frankfurt, Germany. Their discoveries were the result of the first organized team effort to optimize the biological activity of a lead compound through systematic chemical modifications. [1] This scheme is the basis for most modern pharmaceutical research. Both Salvarsan and Neosalvarsan are prodrugs  that is, they are metabolised into the active drug in the body.

Although, like Salvarsan, it was originally believed to contain an arsenic-arsenic double bond, this is now known to be incorrect for Salvarsan. [2] Presumably, Neosalvarsan also exists as a mixture of differently sized rings with arsenic-arsenic single bonds.

References

  1. Strebhardt K, Ullrich A (May 2008). "Paul Ehrlich's magic bullet concept: 100 years of progress". Nature Reviews. Cancer. 8 (6): 473–480. doi:10.1038/nrc2394. PMID   18469827. S2CID   30063909.
  2. Lloyd NC, Morgan HW, Nicholson BK, Ronimus RS (2005). "The Composition of Ehrlich's Salvarsan: Resolution of a Century-Old Debate" (PDF). Angewandte Chemie. 44 (6). International Ed. in English: 941–944. Bibcode:2005ACIE...44..941L. doi: 10.1002/anie.200461471 . hdl:10289/207. ISSN   1521-3773. PMID   15624113.